Autolus Therapeutics (AUTL) pipeline and stated timing

Name in SEC filings: Autolus Therapeutics plc

Pipeline at a glance

Program	Event	Stage	Stated timing	Filing
AUTO8	/data readout	Phase 1	end of 2026	10-Q · Aug 11, 2026

Source: ORION, orionbiotechai.com/company/AUTL, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/AUTL

Nearest upcoming stated timing: AUTO8 · Topline/data readout · end of 2026

SEC sources last checked Oct 18, 2026.

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

AUTO8

Matched

Topline/data readoutend of 2026

Stage: Phase 1SEC filing · “Phase 1”

Public float: $548,891,288 · as of Jun 30, 2025 · SEC filing

The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026.

10-Q · Filed Aug 11, 2026 · Last checked Oct 18, 2026

Source details

Accession 0001730463-26-000123

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of Oct 19, 2026.

Program / event	Stated period and SEC wording	Disclosure in stated period
AUTO8Clinical results	end of 2026 “The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026.” Filed Aug 11, 2026 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
AUTO8Clinical results	end of 2026 “initial data from the trial at the end of 2026” Filed May 14, 2026 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
AUTO8Clinical results	end of 2026 “initial data is expected to be reported at the end of 2026.” Filed May 14, 2026 · 10-Q	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
AUTO8Clinical results	end of 2026 “Initial data from the Phase 1 trial are expected to be reported at the end of 2026.” Filed Mar 27, 2026 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.
AUTO8Clinical results	end of 2026 “initial data is expected to be reported at the end of 2026.” Filed Mar 27, 2026 · 10-K	Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch AUTL

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for AUTL. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window: The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date: The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q: First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original: The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status: One of seven labels set by founder review of the original filings. Definitions: Methodology.

See AUTL in the calendar · Review labels and methodology